# What's new in systemic sclerosis research

## Randomized Controlled Trials

*(No papers classified in this section)*

---

## Observational Studies (cohort studies, case-control studies, cross-sectional studies)

**Association of Systemic Sclerosis With Premature Ventricular Complexes and Cardiac Arrest: A National Inpatient Sample Analysis for 2021.**  
This large-scale inpatient analysis found that systemic sclerosis is independently associated with an increased frequency of premature ventricular complexes and cardiac arrest, emphasizing the need for close cardiac monitoring in these patients.  
*Citation: Association of Systemic Sclerosis With Premature Ventricular Complexes and Cardiac Arrest: A National Inpatient Sample Analysis for 2021, Cureus, 05/01/2025, PMID: [40585648](https://www.ncbi.nlm.nih.gov/pubmed/40585648)*

**Distribution of white matter hyperintensity in systemic sclerosis patients: a monocenter, cross-sectional magnetic resonance imaging study.**  
This study identified a higher prevalence and distinctive pattern of deep white matter hyperintensities in systemic sclerosis patients compared to healthy controls, with differences also observed between SSc subtypes.  
*Citation: Distribution of white matter hyperintensity in systemic sclerosis patients: a monocenter, cross-sectional magnetic resonance imaging study, Rheumatology (Oxford, England), 06/23/2025, PMID: [40581380](https://www.ncbi.nlm.nih.gov/pubmed/40581380)*

**The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis.**  
In this retrospective study, sacubitril/valsartan therapy improved cardiac function and reduced biomarker levels in systemic sclerosis patients with heart failure, with hypotension as a notable side effect.  
*Citation: The Effectiveness of Sacubitril/Valsartan in Systemic Sclerosis Patients with Heart Failure: A Retrospective Analysis, Journal of clinical medicine, 06/08/2025, PMID: [40565799](https://www.ncbi.nlm.nih.gov/pubmed/40565799)*

**Antibody Profile of Systemic Sclerosis and Mixed Connective Tissue Disease and Its Relationship with Lung Fibrosis and Pulmonary Hypertension.**  
This study found that anti-Scl-70 antibodies correlate positively with lung fibrosis in systemic sclerosis and mixed connective tissue disease, while anti-centromere, anti-histone, and anti-nucleosome antibodies appear protective.  
*Citation: Antibody Profile of Systemic Sclerosis and Mixed Connective Tissue Disease and Its Relationship with Lung Fibrosis and Pulmonary Hypertension, International journal of molecular sciences, 06/13/2025, PMID: [40565147](https://www.ncbi.nlm.nih.gov/pubmed/40565147)*

**Computed tomography-derived quantitative imaging biomarkers enable the prediction of disease manifestations and survival in patients with systemic sclerosis.**  
Quantitative CT body composition biomarkers outperformed traditional clinical parameters in predicting survival and disease complications in systemic sclerosis, supporting their potential integration into clinical practice.  
*Citation: Computed tomography-derived quantitative imaging biomarkers enable the prediction of disease manifestations and survival in patients with systemic sclerosis, RMD open, 06/25/2025, PMID: [40562681](https://www.ncbi.nlm.nih.gov/pubmed/40562681)*

**Increased Frequency of the Non-Dipper Blood Pressure Pattern in Patients with Systemic Sclerosis: Insights from 24-Hour Ambulatory Monitoring.**  
Systemic sclerosis patients exhibit a significantly higher prevalence of non-dipper blood pressure patterns, suggesting disruptions in circadian blood pressure regulation and highlighting the need for tailored monitoring.  
*Citation: Increased Frequency of the Non-Dipper Blood Pressure Pattern in Patients with Systemic Sclerosis: Insights from 24-Hour Ambulatory Monitoring, Journal of personalized medicine, 06/15/2025, PMID: [40559115](https://www.ncbi.nlm.nih.gov/pubmed/40559115)*

---

## Basic Science Research

**Matrix stiffness regulates profibrotic fibroblast differentiation and fibrotic niche activation in systemic sclerosis.**  
This study reveals that increased matrix stiffness drives profibrotic fibroblast differentiation and sustains fibrosis in systemic sclerosis, highlighting biomechanical cues as potential therapeutic targets.  
*Citation: Matrix stiffness regulates profibrotic fibroblast differentiation and fibrotic niche activation in systemic sclerosis, Annals of the rheumatic diseases, 06/26/2025, PMID: [40579317](https://www.ncbi.nlm.nih.gov/pubmed/40579317)*

**Antimitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility.**  
Research shows that antimitochondrial antibodies in systemic sclerosis can penetrate enteric neurons and mitochondria, alter cellular function, and are associated with gastrointestinal dysmotility.  
*Citation: Antimitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility, Annals of the rheumatic diseases, 06/27/2025, PMID: [40581581](https://www.ncbi.nlm.nih.gov/pubmed/40581581)*

---

## Meta-analyses and Systematic Reviews

**The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review.**  
Mesenchymal stem cell therapy shows promise for several immune-mediated inflammatory skin diseases, including systemic sclerosis, with generally mild adverse events and potential benefit for refractory cases, though more controlled trials are needed.  
*Citation: The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review, Dermatology reports, 07/01/2025, PMID: [40590534](https://www.ncbi.nlm.nih.gov/pubmed/40590534)*

**Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis.**  
This meta-analysis found that mycophenolate mofetil provides clinically and statistically significant improvement in skin fibrosis in systemic sclerosis, supporting its frontline use though further studies are recommended.  
*Citation: Efficacy of Mycophenolate Mofetil in Treating Skin Fibrosis in Systemic Sclerosis: A Systematic Review and Meta-Analysis, Journal of clinical medicine, 06/12/2025, PMID: [40565931](https://www.ncbi.nlm.nih.gov/pubmed/40565931)*

---

## Narrative Reviews

**New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.**  
This review synthesizes advances in organ-based management of systemic sclerosis and highlights emerging, personalized therapies that offer promise for altering disease trajectory and supporting targeted intervention.  
*Citation: New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025, RMD open, 07/01/2025, PMID: [40592721](https://www.ncbi.nlm.nih.gov/pubmed/40592721)*

**[CAR T cells in non-malignant diseases].**  
This review summarizes early pilot studies in using CD19-targeted CAR T cells for autoimmune diseases including systemic sclerosis, emphasizing promising remission rates and new therapeutic concepts being explored.  
*Citation: [CAR T cells in non-malignant diseases], Innere Medizin (Heidelberg, Germany), 06/30/2025, PMID: [40586812](https://www.ncbi.nlm.nih.gov/pubmed/40586812)*

**Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects.**  
A review of CAR T-cell therapy in rheumatic diseases describes advances, early clinical success in systemic sclerosis, and future directions for optimizing efficacy and mitigating side effects.  
*Citation: Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects, Journal of rheumatic diseases, 07/01/2025, PMID: [40584766](https://www.ncbi.nlm.nih.gov/pubmed/40584766)*

**[Pharmacological inhibition of fibrosis exemplified by systemic sclerosis : Possibilities and limits].**  
The review discusses recent insights and clinical trials in targeting fibrosis in systemic sclerosis, noting ongoing development of therapies and highlighting remaining questions and limitations.  
*Citation: [Pharmacological inhibition of fibrosis exemplified by systemic sclerosis : Possibilities and limits], Innere Medizin (Heidelberg, Germany), 07/01/2025, PMID: [40576794](https://www.ncbi.nlm.nih.gov/pubmed/40576794)*

**Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.**  
This review discusses promising biomarkers and current therapies for progressive fibrosing interstitial lung disease in connective tissue diseases like systemic sclerosis, but notes the lack of a universal predictor or treatment.  
*Citation: Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease, Biomedicines, 06/13/2025, PMID: [40564181](https://www.ncbi.nlm.nih.gov/pubmed/40564181)*

**Molecular Pathogenesis of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Narrative Review.**  
This review provides a detailed update on the molecular mechanisms of pulmonary arterial hypertension secondary to connective tissue diseases, focusing on recent advances in biomarkers, immune dysregulation, and relevant animal models.  
*Citation: Molecular Pathogenesis of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Narrative Review, Biomolecules, 05/27/2025, PMID: [40563413](https://www.ncbi.nlm.nih.gov/pubmed/40563413)*

**Chimeric antigen receptor T cell therapy for autoimmune diseases.**  
Highlighting the recent advances and early clinical efficacy of CAR T cell therapies in autoimmune diseases including systemic sclerosis, this review discusses mechanisms, challenges, and future directions.  
*Citation: Chimeric antigen receptor T cell therapy for autoimmune diseases, Current opinion in immunology, 08/01/2025, PMID: [40561659](https://www.ncbi.nlm.nih.gov/pubmed/40561659)*

**Crosstalk between oxidative stress, mitochondrial dysfunction, chromosome instability, and the activation of the cGAS-STING/IFN pathway in systemic sclerosis.**  
This review discusses the major role of cellular stress responses and cGAS-STING pathway activation in SSc pathogenesis, and highlights therapeutic potential for targeting these mechanisms.  
*Citation: Crosstalk between oxidative stress, mitochondrial dysfunction, chromosome instability, and the activation of the cGAS-STING/IFN pathway in systemic sclerosis, Ageing research reviews, 08/01/2025, PMID: [40562314](https://www.ncbi.nlm.nih.gov/pubmed/40562314)*

---

## Case Reports & Case Series

**Case Report: Chalk-Like Synovial Fluid and Calcified Synovium in Systemic Sclerosis Overlapping With Rheumatoid Arthritis Stabilized by Rituximab.**  
No abstract available for summarization.  
*Citation: Case Report: Chalk-Like Synovial Fluid and Calcified Synovium in Systemic Sclerosis Overlapping With Rheumatoid Arthritis Stabilized by Rituximab, International journal of rheumatic diseases, 07/01/2025, PMID: [40590522](https://www.ncbi.nlm.nih.gov/pubmed/40590522)*

**Nailfold capillaroscopy in myositis: A case series.**  
This case series describes four myositis patients where nailfold capillaroscopy aided diagnosis, highlighting its value beyond systemic sclerosis and its utility in challenging or atypical cases.  
*Citation: Nailfold capillaroscopy in myositis: A case series, SAGE open medical case reports, 01/01/2025, PMID: [40584538](https://www.ncbi.nlm.nih.gov/pubmed/40584538)*

**Gastrointestinal Complications of Systemic Sclerosis: A Case Report.**  
A case report of an elderly patient with systemic sclerosis/CREST syndrome details how severe gastrointestinal complications contributed to morbidity and mortality, underscoring the seriousness of GI involvement.  
*Citation: Gastrointestinal Complications of Systemic Sclerosis: A Case Report, Cureus, 06/01/2025, PMID: [40583919](https://www.ncbi.nlm.nih.gov/pubmed/40583919)*

**Clinical Images: Interstitial lung disease in Sjögren disease in association with systemic sclerosis.**  
No abstract available for summarization.  
*Citation: Clinical Images: Interstitial lung disease in Sjögren disease in association with systemic sclerosis, ACR open rheumatology, 07/01/2025, PMID: [40566703](https://www.ncbi.nlm.nih.gov/pubmed/40566703)*

**An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis.**  
This paper reports the first use of dual-targeting CAR-NK cells in a patient with severe systemic sclerosis, resulting in marked improvement, B cell depletion, and reversal of fibrosis, indicating a promising new therapeutic approach.  
*Citation: An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis, Cell, 06/16/2025, PMID: [40562027](https://www.ncbi.nlm.nih.gov/pubmed/40562027)*

---

## Other

**Safety profile of letrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports.**  
Letrozole's analysis in real-world and case report data revealed new adverse drug reactions, including systemic sclerosis and acute kidney injury, underlining the importance of vigilance for rare toxicities.  
*Citation: Safety profile of letrozole in the real world: a disproportionality analysis of FAERS database and systematic review of case reports, Expert opinion on drug safety, 07/09/2025, PMID: [40590361](https://www.ncbi.nlm.nih.gov/pubmed/40590361)*

**The correlation between retinal microvascular changes by optical coherence tomography angiography and nailfold capillaroscopic findings in patients with systemic sclerosis.**  
Nailfold capillary density measured by capillaroscopy correlates with retinal vessel density, suggesting the utility of combining OCT angiography and capillaroscopy for microvascular assessment in systemic sclerosis.  
*Citation: The correlation between retinal microvascular changes by optical coherence tomography angiography and nailfold capillaroscopic findings in patients with systemic sclerosis, Journal of rheumatic diseases, 07/01/2025, PMID: [40584763](https://www.ncbi.nlm.nih.gov/pubmed/40584763)*

**Absence of functional autoantibodies in systemic sclerosis: is now the right time to broaden reactome analysis? Comment on "Absence of Functional Autoantibodies Targeting Angiotensin II Receptor Type 1 and Endothelin-1 Type A Receptor in Circulation and Purified IgG From Patients With Systemic Sclerosis" published in Arthritis Rheumatology.**  
No abstract available for summarization.  
*Citation: Absence of functional autoantibodies in systemic sclerosis: is now the right time to broaden reactome analysis?, Arthritis & rheumatology (Hoboken, N.J.), 06/30/2025, PMID: [40583579](https://www.ncbi.nlm.nih.gov/pubmed/40583579)*

**Expert consensus on interstitial lung disease associated with systemic autoimmune diseases. Executive summary.**  
This expert consensus presents up-to-date recommendations for screening, diagnosis, and treatment of interstitial lung disease in systemic autoimmune diseases, including systemic sclerosis, aiming to standardize and improve clinical care.  
*Citation: Expert consensus on interstitial lung disease associated with systemic autoimmune diseases. Executive summary, Revista clinica espanola, 06/27/2025, PMID: [40582403](https://www.ncbi.nlm.nih.gov/pubmed/40582403)*

**Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosis.**  
Quantitative HRCT analysis was shown to be a useful surrogate for assessing nintedanib efficacy in stabilizing lung fibrosis in systemic sclerosis and IPF, supporting its use in future clinical trials.  
*Citation: Quantitative HRCT as a surrogate outcome measure for nintedanib treatment in systemic sclerosis-interstitial lung disease and idiopathic pulmonary fibrosis, Joint bone spine, 06/24/2025, PMID: [40571119](https://www.ncbi.nlm.nih.gov/pubmed/40571119)*

**Utility of Right Ventricular Free Wall Systolic Strain for Prediction of Systemic Sclerosis associated Pulmonary Arterial Hypertension.**  
No abstract available for summarization.  
*Citation: Utility of Right Ventricular Free Wall Systolic Strain for Prediction of Systemic Sclerosis associated Pulmonary Arterial Hypertension, European heart journal. Cardiovascular Imaging, 06/17/2025, PMID: [40569887](https://www.ncbi.nlm.nih.gov/pubmed/40569887)*

**Letter to the editor: "A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES‑D, BDI, and PHQ-9 self‑assessment questionnaires".**  
No abstract available for summarization.  
*Citation: Letter to the editor: "A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES‑D, BDI, and PHQ-9 self‑assessment questionnaires", Clinical rheumatology, 06/28/2025, PMID: [40580413](https://www.ncbi.nlm.nih.gov/pubmed/40580413)*

---